What is Reshape?
Founded in 2018 and headquartered in Copenhagen, Denmark, Reshape provides a sophisticated solution for biological researchers, enabling the automation of visual experiments. Its platform captures and analyzes data points with exceptional speed and accuracy, thereby minimizing errors and maximizing the time researchers can dedicate to value-adding tasks. This technological advancement guides microbiological research with precision, fostering a deeper understanding of natural processes and accelerating the pace towards significant scientific breakthroughs.
How much funding has Reshape raised?
Reshape has raised a total of $28.1M across 2 funding rounds:
Angel/Seed
$8.1M
Series A
$20M
Angel/Seed (2023): $8.1M with participation from Acme Capital, Y Combinator, and FundersClub
Series A (2024): $20M led by Y Combinator, Astanor Ventures, and Acme
Key Investors in Reshape
Acme Capital
ACME Capital is an early-stage venture capital firm based in San Francisco, known for investing in breakthrough enabling technologies and business model innovations that disrupt massive sectors. They partner with entrepreneurs globally who are developing significant technologies with a positive impact for future consumers.
Y Combinator
Y Combinator, established in 2005 and located in Mountain View, California, is a renowned accelerator that provides seed funding for startup businesses and acts as a key investor for emerging companies.
Astanor Ventures
Astanor Ventures is dedicated to transforming the agrifood system by fostering innovation and impact from soil and sea to gut. They invest in visionary founders and solutions that promote sustainability, health, and equity within the global food system.
What's next for Reshape?
The recent major strategic investment of $20M positions Reshape for accelerated scaling and further innovation in its field. This substantial capital infusion, contributing to the company's overall $28.1M in funding, suggests a transition into a growth phase, likely focused on expanding its market reach, enhancing its platform's capabilities, and potentially forging new strategic partnerships. The company's ability to attract such significant backing indicates strong investor confidence in its mission to revolutionize scientific research through automation and data-driven insights.
See full Reshape company page
